---
document_datetime: 2024-05-13 15:49:46
document_pages: 4
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/anagrelide-viatris-previously-anagrelide-mylan-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
document_name: anagrelide-viatris-previously-anagrelide-mylan-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
version: success
processing_time: 2.8486875
conversion_datetime: 2025-12-18 08:52:22.04988
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.1-arm64-arm-64bit-Mach-O
---
## Anagrelide Viatris

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                           | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|-------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| T/0015               | Transfer of Marketing Authorisation                                                             | 01/03/2024                          | 09/04/2024                                  | SmPC, Labelling and PL           |           |
| IG/1688              | A.2.a - Administrative change - Change in the (invented) name of the medicinal product for CAPs | 15/01/2024                          | 27/03/2024                                  | SmPC, Labelling and              |           |

1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

|                   |                                                                                                                                                                                                                                                              |            |            | PL          |                                                                                                                                                                                                                                                                                                                                                                    |
|-------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/208/2 02209 | Periodic Safety Update EU Single assessment - anagrelide                                                                                                                                                                                                     | 12/05/2023 | n/a        |             | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                  |
| IB/0013           | C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation                                                                                                                | 28/04/2023 | n/a        |             |                                                                                                                                                                                                                                                                                                                                                                    |
| N/0012            | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                             | 22/02/2023 | 27/03/2024 | PL          |                                                                                                                                                                                                                                                                                                                                                                    |
| R/0010            | Renewal of the marketing authorisation.                                                                                                                                                                                                                      | 15/09/2022 | 21/11/2022 | SmPC and PL | Based on the review of data on quality, safety and efficacy, the CHMP considered that the benefit-risk balance of Anagrelide Mylan in the approved indication remains favourable and therefore recommended the renewal of the marketing authorisation with unlimited validity. The PI is brought in line with with the SmPC guideline and the latest QRD template. |
| IB/0009           | C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH | 13/05/2022 | 20/10/2022 | SmPC and PL |                                                                                                                                                                                                                                                                                                                                                                    |
| IB/0008           | C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by         | 13/10/2021 | 20/10/2022 | SmPC        |                                                                                                                                                                                                                                                                                                                                                                    |

<div style=\"page-break-after: always\"></div>

|                   | the MAH                                                                                                                                                                                                                                                      |            |            |                                  |                                   |
|-------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|-----------------------------------|
| T/0007            | Transfer of Marketing Authorisation                                                                                                                                                                                                                          | 12/08/2021 | 22/09/2021 | SmPC, Labelling and PL           |                                   |
| PSUSA/208/2 02009 | Periodic Safety Update EU Single assessment - anagrelide                                                                                                                                                                                                     | 09/04/2021 | n/a        |                                  | PRAC Recommendation - maintenance |
| IB/0005           | C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH | 26/05/2020 | 09/07/2021 | SmPC, Annex II, Labelling and PL |                                   |
| PSUSA/208/2 01909 | Periodic Safety Update EU Single assessment - anagrelide                                                                                                                                                                                                     | 17/04/2020 | n/a        |                                  | PRAC Recommendation - maintenance |
| PSUSA/208/2 01809 | Periodic Safety Update EU Single assessment - anagrelide                                                                                                                                                                                                     | 11/04/2019 | n/a        |                                  | PRAC Recommendation - maintenance |
| N/0003            | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                             | 15/03/2019 | 09/07/2021 | PL                               |                                   |
| IAIN/0001/G       | This was an application for a group of variations. B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging          | 13/09/2018 | n/a        |                                  |                                   |

<div style=\"page-break-after: always\"></div>

| site   |
|--------|